

1 **A multi-centric, cross-sectional study on COVID-19 in Bangladesh: Clinical**
2 **epidemiology and short-term outcomes in recovered individuals**

3
4
5 Adnan Mannan^{1*}, H. M. Hamidullah Mehedi², Naim Uddin Hasan A Chy³, Md. Omar Qayum⁴,
6 Farhana Akter⁵, Abdur Rob², Prasun Biswas⁶, Sanjida Hossain⁷, Mustak Ibn Ayub⁸

7
8 ¹ Department of Genetic Engineering & Biotechnology, Faculty of Biological Sciences,
9 University of Chittagong, Chattogram-4331, Bangladesh.

10 ² Department of Medicine, 250 bedded Chittagong General Hospital, Chattogram, Bangladesh

11 ³ Health Economics Research Group, Department of Economics, Faculty of Social Sciences,
12 University of Chittagong, Chattogram-4331, Bangladesh.

13 ⁴ Office of the Director, Institute of Epidemiology, Disease Control & Research (IEDCR),
14 Dhaka, Bangladesh.

15 ⁵ Department of Endocrinology, Chittagong Medical College, Chattogram, Bangladesh

16 ⁶ Department of Pathology, Mymensingh Medical College (MMC), Mymensingh, Bangladesh

17 ⁷ Corona unit, Dhaka Mohanagar General Hospital, Dhaka, Bangladesh.

18 ⁸ Department of Genetic Engineering & Biotechnology, University of Dhaka, Ramna, Dhaka-
19 1000, Bangladesh.

20
21 *Corresponding Author: Adnan Mannan, adnan.mannan@cu.ac.bd, Phone: +8801716903485.

22 **Running title:** Clinical epidemiology of COVID-19 in Bangladesh.

23 **Keywords:** Bangladesh, COVID-19, Asymptomatic, Epidemiology, Comorbidities, post
24 COVID-19 complications.

25 **Acknowledgements:** Authors would like to thank the volunteers and research assistants of
26 Disease Biology and Molecular Epidemiology Research Group, Chittagong for their help and
27 contribution to complete this study.

30 **Author contributions**

31
32 AM, HMM, FA and AR designed the study. MOQ, MIA, PB and SH reviewed the literature,
33 extracted the data and checked the extracted data. NHC and AM planned and conducted the
34 analysis. MOQ, HMM and MIA wrote the first draft and all authors reviewed and approved the
35 final manuscript paper; approved the final version and agreed to be accountable for the work.

36

37 **Conflicts of interest:**

38 The authors would like to declare that there is no known contending financial interest or personal
39 relationships that could affect the work reported in this paper.

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58 **Abstract**

59 **Background:** COVID-19 turned into a global pandemic rapidly. This study was aimed to
60 investigate SARS-CoV-2 associated epidemiology and clinical outcomes in Bangladesh in order
61 to understand the future course of COVID-19 pandemic and develop prevention approaches.

62 **Design and Methods:** A cross-sectional retrospective study was conducted for a sample of 1,021
63 RT-PCR confirmed COVID-19 cases admitted in six different hospitals in Bangladesh and who
64 recovered four weeks prior to the interview date.

65 **Results:** Of the total sample, 111 (10.9%) cases were asymptomatic while the number of
66 symptomatic cases were 910 (89.1%). Higher prevalence of COVID-19 persisted in the male
67 population (75%), cohorts having B (+) ve blood group (36.3%) and for the 31-40 age group.
68 More than 85% of the sample reported a BCG vaccination mark. Common symptoms observed
69 in our study samples were fever (72.4%), cough (55.9%), loss of taste (40.7%) and body ache
70 (40%); whereas among the biochemical parameters, Neutrophil (46.4%), D-dimer (46.1%), and
71 Ferritin (37.9%) levels were found elevated. Post-COVID complications including pain (31.8%),
72 loss of concentration (24.4%) and anxiety or depression (23.1%) were also found significantly
73 prevalent in the symptomatic cases with commodities.

74 **Conclusion:** Our study has shown that adult males aged in between 31-40 in Bangladesh are
75 more vulnerable to being infected with COVID-19. The study also indicates a rising trend of the
76 asymptomatic cases as the pandemic progresses deeper in time, and hence, deployment of
77 interventions to curb further spread of community infection is necessary to avoid the grave
78 outcomes of COVID-19 in Bangladesh.

79

80 **Keywords:** Bangladesh, COVID-19, Asymptomatic, Epidemiology, Comorbidities, post
81 COVID-19 complications.

82

83

84 **Introduction:**

85 The Coronavirus Disease 2019 or COVID-19 is a contagious disease of the respiratory system.¹
86 In terms of genetic characteristics, SARS-CoV-2 is significantly diverse from SARS-CoV and
87 MERS-CoV.^{2,3} The virus's rapid progression around the globe has unfolded a variety of clinical
88 manifestations in different geographical locations. Severe prognosis of COVID-19 has been
89 reported to be associated with comorbidities including diabetes, hypertension, cardiovascular
90 disease, chronic obstructive pulmonary disease (COPD), malignancy, and chronic liver disease.⁴
91 With a population of more than 161 million people, Bangladesh stands eighth among the most
92 populated countries in the world.⁵ In Bangladesh, as of 9 October, 2020, infections from SARS-
93 CoV-2 has spiked to nearly 375,870 individuals while the death count figured to 5477 people
94 (<https://iedcr.gov.bd/>). In regards to the clinical outcomes of COVID-19 and its association with
95 various pathophysiological factors, no comprehensive study has been conducted in Bangladesh.
96 As some of the studies were not conducted for a large sample size,⁶⁻⁸ understanding a bigger
97 picture of the aforementioned relationship of COVID-19 symptoms with comorbidities and
98 biochemical parameters from previous studies was not possible. Especially, the long-term
99 complications among patients recovered from COVID-19 have not been conducted with
100 necessary rigor and comprehension. Investigating the epidemiological characteristics of
101 individuals diagnosed with COVID-19 in Bangladesh will help in providing a proper insight of
102 the clinical characterization and patterns in progression of the disease. Therefore, it is vital to
103 examine these aspects and factors related to the outcomes of COVID-19 for enacting appropriate
104 means of prevention and treatment.

105 Since to this date, this study is a pioneering approach for the epidemiological characterization of
106 COVID-19 individuals in Bangladesh, data related to the clinical aspects of COVID-19 is scarce,
107 we managed to create a large sample size for our study by collecting data for a consecutive three
108 months during the pandemic. This study aimed to investigate the patterns and array of symptoms
109 in confirmed COVID-19 individuals as well as assess its relationship with the presence of
110 comorbidities and results from biochemical assays with various other preliminary long-term
111 clinical expositions post recovery.

112

113

114

115

116

117

118

119

120

121

122

123

124

125 **Methods**

126 *Study design:*

127 A cross-sectional retrospective study was conducted among the cases confirmed to be COVID-
128 19 positive following assessment by RT-PCR using any one of the following samples: throat
129 swabs / nasal swabs /blood. These COVID-19 diagnosed patients were admitted in six different
130 hospitals in Bangladesh. Scrutinization of post COVID-19 clinical characteristics was done upon
131 each subject's discharge from the hospital and after confirming that these subjects were indeed
132 COVID-19 free by conducting two consecutive RT-PCR assays 24 hours apart. Recovered
133 patients (according to RT-PCR negative result) at least four weeks before the interview were
134 considered for this study. We also categorized all positive patients into two categories
135 (symptomatic and asymptomatic) according to the presence of any one of the established
136 symptoms referred by WHO/CDC.

137 *Study sites and sample size:*

138 The study was conducted in six hospitals having specialized units (following government
139 instructions) for isolating and treating COVID-19 individuals from two different divisions of
140 Bangladesh namely Dhaka (Dhaka Mohanogor General Hospital and Narayanganj Sadar
141 Hospital) and Chattogram (Chittagong General Hospital, Chittagong Medical College Hospital,
142 Chattogram Field Hospital and Chandpur Sadar Hospital). The study period started from 1 April
143 2020 and ended on 30 June 2020.

144 *Data collection and case enrollment:*

145 The physicians collected data relevant to the study retrospectively by interviewing 1021 COVID-
146 19 patients over the telephone and all data were recorded into a preset Google Form. After

147 double checking each information, the Google Forms were submitted and stored in our database.
148 Medical prescriptions, hospital records were also accessed and matched with patients' data
149 obtained through the interview. Questionnaires included patient's socio-demographic
150 information, clinical manifestations, biochemical parameters, behavioral practice, comorbidities,
151 medications, vitals, laboratory tests, electrocardiogram results, inpatient medications, treatments
152 and outcomes (including length of stay, discharge, re-admission, and mortality).

153 ***Exclusion criteria:***

154 In this study, deceased patients and those who were not interested to participate or did not give
155 consent to data collection and usage for research purposes were not included.

156 ***Ethical consideration:***

157 The protocol was approved by IRB of 250 bedded General Hospital, Chattogram, Bangladesh.
158 The ethical approval number is 00981.

159 ***Statistical analysis:***

160 Descriptive statistical analyses were performed expressing categorical variables with numbers
161 and proportions. They were compared using chi-square test and Fisher's exact test. P values of
162 less than or equal to 0.05 (two-sided) were considered statistically significant. Multivariate
163 logistic regressions were performed to identify the predictors of post-COVID long-term
164 complications. All statistical analyses were performed using Stata/MP 14.0 and GraphPad Prism.
165 The study considered COVID patients showing no symptoms of infection as asymptomatic and
166 those showing at least one of the typical symptoms as symptomatic. Similarly, patients with at
167 least one type of comorbidity were considered comorbid and those with no comorbidity were
168 considered non-comorbid patients.

169 **Results**

170 *Demographic information and vaccination history of COVID-19 patients in the sample:*

171
172 Of 1,021 COVID-19 inpatients, a total of 111(10.9%) were found to be asymptomatic, while the
173 number of symptomatic cases were 910 (89.1%) which was predominant within the sample
174 (Table-1).

175 As shown in Table-1, a subject's age was found to have association with him/her being
176 asymptomatic or symptomatic ($p=0.000$). Higher proportions of asymptomatic cases were found
177 under the age groups of 0-9 (7.2%), 10-19 (7.2%), and 20-29 (28.8%). Common to both
178 symptomatic and asymptomatic groups, the proportion of males was greater than that of females,
179 the figures being 64.9% and 76.1% respectively ($p = 0.01$). Individuals in the symptomatic group
180 showed more likelihood towards being overweight (46.4%) and obese (24.6%). A significant
181 bivariate relationship was found (with a p value of 0.009) between blood group and a patient's
182 being symptomatic or asymptomatic. More than 90% of all patients received all required basic
183 vaccines, and almost 85% had a clear BCG scar on their arms. Diabetes was the most prevalent
184 comorbid condition (19.3%), followed by respiratory (8.4%) and cardiovascular (7.7%) diseases
185 within the total sample. An over the time trend in asymptomatic and symptomatic COVID-19
186 cases was also examined. The bar graph in Figure-1 clearly illustrates an upward trend among
187 asymptomatic COVID-19 cases with time while the trend for symptomatic cases remained more
188 or less similar.

189

190

191

192 ***Clinical manifestations of COVID-19 patients:***

193

194 Table-2 presents counts and proportions of usual signs and symptoms as observed in individuals
195 diagnosed with COVID-19. Of the total sample, 474 (51%) patients experienced a body
196 temperature exceeding 1010 F, while for 368 (39.5%) patients the body temperature ranged from
197 990 F to 1010 F. The oxygen saturation rate went below 90% for 19.3% of the patients, and
198 another 8% patient experienced a low saturation level of 90% to 92.9%. The systolic and
199 diastolic blood pressure measures were found to be greater than 159 mmHg and 99 mmHg,
200 respectively for 4.7% of the total cases. The most prevalent symptoms among the cases in order
201 of prevalence rate were fever (72.4%), cough (55.9%), taste loss (40.7%), body ache (40%),
202 smell loss (36.9%), breathing difficulty (25.9%), and sore throat (23.7%).

203

204 ***Biochemical parameters of COVID-19 patients in the sample:***

205

206 For a substantial number of cases within the sample, biochemical assay results were found to be
207 deviant from the normal range for each of the markers measured in the analyte (Figure-2A).
208 Neutrophils and D-dimer were found to be high for about 50% of the patients in the sample
209 while for approximately 40% of patients, the diagnostic tests showed a high level of Glucose,
210 Ferritin, CRP, and SGPT. Among other parameters, Troponin was high for 30% of the patients,
211 while Creatinine, WBC-TC, and ESR were at elevated levels for around 20% of the patients. A
212 low lymphocyte count was found for 40% of the patients while laboratory test results for 10% of
213 the patients reported low platelet count as well.

214

215 ***Medication history during the tenure of COVID-19 persistence for cases:***

216

217 Individuals with COVID-19 during the tenure of their SARS-CoV-2 positive status took some
218 day-to-day medications along with antibiotics (Figure-2B). Of the antibiotics, 55.71% of the
219 cases took Azithromycin solely while the number stood at 74% when it was consumed in
220 combination with other therapeutic drugs establishing a higher proportion in terms of intake as
221 compared to the other antibiotics frequently taken. 8.18% of the patients took only Doxycycline
222 and 14.7% took Doxycycline but in combination with other medications, while for Ivermectin
223 the sole consumption and consumption in combination stood at 6.14% and 11.2% respectively.
224 Of the other types of medications, Montelukast was taken by 0.3% and 22.5% of the patients
225 took multiple other types of therapeutic drugs. 6.13% of the patients did not take any
226 medications during COVID-19.

227 ***Preliminary long-term health issues associated with COVID-19:***

228

229 The most prevalent post-recovery complications that were reported included sleep disturbance
230 (32%), pain and discomfort (31.8%), lack of concentration (24.4%), anxiety and depression
231 (23.1%), memory loss (19.5%), and complications with mobility (17.7%), as shown in Table 3.
232 Considering comorbidity as determinant, chi-square tests for post-recovery complications
233 returned significant deviations between individuals having comorbidity and those without for all
234 reported complications but panic attacks. Comorbid patients were found to be more likely to
235 experience mobility problem (26%), problems performing usual activities (14%), pain and
236 discomfort (40%), anxiety and depression (28.5%), sleep disturbances (41.3%), concentration
237 loss (28.5%), and memory loss (24.6%) than those without any comorbid conditions. We

238 observed significant differences in proportion between the two groups for all complications
239 except panic attacks, giving a clear conception on the comparison between the results of the
240 aforesaid cases with those found for comorbid and non-comorbid cases. Columns in Table-4
241 contain estimated results from logit models designed for post-recovery complications. As the
242 adjusted odd ratios indicate, the respiratory disease caused each outcome of memory loss and
243 pain and discomfort at 5% level and sleep disturbance at 1%. Finally, it was found that taking
244 drugs for a long time significantly increased the probability of losing memory, concentration,
245 and having sleep disturbance at 1% level and anxiety and depression at 5% level.

246

247 ***Contact History of the COVID-19 Patients in this Sample:***

248

249 This study also assessed the contact history of patients included in the study sample, focusing on
250 multiple variables representing direct and indirect contacts (Supplementary file, Table-S1). As
251 Table S1 shows 50% of the diagnosed cases came in close contact with other COVID-19 positive
252 individuals, while 40.6% patients of the total sample had family members diagnosed with
253 COVID-19. A total of 608 (62%) patients reported to have an indirect contact, and 466 (48.5%)
254 patients made frequent visits outside their home prior to being infected.

255

256

257

258

259

260

261 **Discussion**

262 In the current study, we investigated 1021 COVID-19 inpatients diagnosed through RT-PCR in
263 six different health facilities in Bangladesh. We believe that the current study will be able to shed
264 light on the epidemiological aspects of COVID-19 during the crisis period. While the study
265 revealed facts aligning with those established globally some observations require further follow
266 up and extensive studies in Bangladesh.

267 Our study has revealed that among the age groups, the 20-39 cohorts showed the highest prone to
268 infection rate (54.7%) and in terms of gender, the prevalence of SARS-CoV-2 infection in males
269 (74.9%) was 3 times more than that in females (25.1%). Several studies from across the globe
270 showed higher median age,⁹⁻¹¹ mean age,¹² or age group⁹ for SARS-CoV-2 infection. We
271 explained the observations in light of demographic and socio-economic situations in Bangladesh.
272 21-40 years is the most preponderant age group in Bangladesh
273 (<https://www.cia.gov/library/publications/the-world-factbook/fields/341.html>), young and
274 middle-aged people mostly fall under the working class and are needed to go are mostly
275 obligated to leave home for work, and hence having higher odds of getting infected.¹³ Females,
276 especially in rural Bangladesh are mostly confined to household work, which might be a cause
277 for less infection among these groups.

278 Among the study subjects, 38.33% had comorbidities. Diabetes was found to be the most
279 prominent comorbidity (19.40%) within the study sample and this fact was reflected in similar
280 studies conducted in China and UK.^{11, 14} Other noteworthy comorbidities were respiratory
281 (8.40%) and cardiovascular diseases (7.70%) and the results obtained from our study aligned to
282 the trends in other countries in terms of high prevalence.^{9, 10, 14}

283 As for the symptoms associated with COVID-19, fever (72.4%) and cough (55.9%) were the
284 most prominent and shared among cases (Table-2). Other clinical manifestations with significant
285 association ($P < 0.01$) were breathing difficulty (25.90%) and chills (12.50%). Diarrhea and GI
286 symptoms were also widely observed in 19.80% cases of COVID-19 in the study sample akin to
287 results obtained from previous studies conducted on the MERS/SARS-CoV pandemics.¹⁵

288 Of the 1,021 COVID-19 positive cases in our sample, 10.9% were asymptomatic which is in
289 accordance with the findings in South Korea and China.^{9, 16} Interesting enough, our observation
290 identified an upward trend for the increase in asymptomatic COVID-19 cases following April
291 2020 (Figure 1). Although no systematic assessment has been done on this aspect, our
292 observation complies with the records and pronouncements of the health professionals and
293 hospital registries in Bangladesh. For getting a better insight on the upward trend of
294 asymptomatic COVID-19 cases further studies and scrutinization are required including a larger
295 sample and dataset.

296 The current study observed different parameters obtained from biochemical assays conducted
297 within the sample and categorized the results as low, normal and high compared to a reference
298 value (Figure 2A). Almost half of the cases had a high level of D-dimer (46.12%) establishing
299 COVID-19 related coagulopathy which is likely a manifestation of profound inflammatory
300 response.¹⁷ For the other parameters, rise in ferritin, CRP, ESR and glucose levels were found in
301 37.92%, 36.08%, 27.37% and 36.48% of the COVID-19 cases respectively. These findings were
302 found to comply with results obtained from similar studies in China conducted on a sample size
303 of 99 and 138 patients respectively.^{18, 19}

304 Our study revealed that 28.75% cases of patients had raised troponin level and it is assumed that
305 this is owing to myocarditis, microangiopathy, myocardial infarction, cytokine storm etc.^{17, 20-23}

306 Elevated liver enzyme, SGPT was also found in 36.83% cases in this study which is also in
307 accordance with in many other papers confirmed by review.²⁴ Although, possible mechanism is
308 yet to be confirmed, majority of these cases reported use of multiple drugs like antibiotics,
309 antivirals, hydroxychloroquine and steroids, which could have contributed to the liver cell
310 damage. Additionally, ischemia and immune mediated injury might be responsible for elevated
311 liver enzyme in Covid-19 positive cases.²⁴ These observations suggest that patients diagnosed
312 with COVID-19 should also undergo follow up diagnosis procedures to check for chronic
313 damages of the heart and liver.

314 Total cell count reports for COVID-19 positive individuals indicated that neutrophil count was
315 elevated in 46.44% of the cases. On the contrary, reduced lymphocyte and platelet counts have
316 been observed among 50% and 10% COVID-19 positive patients. This is in accordance with
317 several other case series around the globe.^{17, 25-28} As our sample included individuals recovered
318 from COVID-19, it is clear that these fluctuating parameters for the blood cell counts did not
319 become lethal to the patient. However, whether they were related to any severe symptom
320 previous to recovery requires further investigation. Our study did not investigate the level of
321 cytokines or other inflammatory mediators in the patients. Further studies in this regard will be
322 helpful in understanding the severity and fatality among COVID-19 patients with respect to
323 immune response mediators.

324 Human-to-human transmission of SARS-CoV-2 has been established as the major mode of
325 spread and several reports provided evidence of transmission of COVID-19 by direct and
326 indirect contact in hospital, family and community settings where interventions were not applied
327 and basic health norms and distancing were not maintained.²⁹⁻³² In our study, majority of the
328 cases (62%) reported indirect contact with confirmed cases, whereas, 48.5% admitted to go out

329 of their homes frequently prior to being infected and diagnosed (Table-S1, supplementary). It
330 further shows that 50% of the respondents had close contact with confirmed cases and 40.6% had
331 COVID-19 positive family members. So, it can be easily concluded from this data that
332 community transmission is very common in Bangladesh and hence social distancing and other
333 preventive measures should be fully implemented to prevent further deterioration.

334 Our study has revealed that antibiotics were heavily suggested as a part of the treatment protocol
335 for the COVID-19 patients (Figure 2B). It has been found that Azithromycin was the most
336 prescribed antibiotic (74%); among them 55.71% were prescribed to take it as a sole drug.
337 Doxycycline and Ivermectin were taken by 14.7% and 11.2% cases respectively; among them
338 8.18% and 6.14% patients got them exclusively. Supportive drugs like montelukast were also
339 taken by a very small number of patients (3%). In Bangladesh, the guideline for COVID-19
340 management allows compassionate use of various antiviral and anti-bacterial drugs along with
341 antimalarial drugs (<https://dghs.gov.bd/index.php/en/>). However, we recommend that the
342 excessive use of Azithromycin and other antibiotics may aggravate the crisis related to the rise of
343 antibiotic resistance in Bangladesh.

344 Whether BCG vaccination may play a significant role in preventing the SARS-CoV-2 infection
345 has remained an area of debate and requires further analysis and assessment. According to the
346 latest WHO brief,³³ BCG does not give protection against SARS-CoV-2 infection. In our study,
347 we have found that 835 (82%) cases have a BCG vaccination mark (Table-1). Therefore,
348 supporting the WHO brief, we infer that BCG vaccination may not play any role in preventing
349 SARS-CoV-2 infection despite some early speculations about it. However, as the subjects are all
350 alive despite SARS-CoV-2 infection, it will be insightful to further investigate whether BCG

351 vaccination may help reduce the severity and hence mortality by modulating the innate immune
352 system.³⁴

353 Our study has also shed light on the relationship between the ABO blood groups and
354 susceptibility to SARS-CoV-2 infection. A number of previous reports suggested individuals
355 having an A (+ve) blood group have the highest risk of being infected while O (+ve) individuals
356 have a comparatively lower risk rate.³⁵⁻³⁷. Our study has showed that the majority of the cases
357 belong to B+ve blood group (35.4%), preceded by O (+ve) 28.2% and A (+ve) 20.3% (Table-1).
358 This ratio is comparable with the population distribution of ABO blood groups (B+ve ~34%,
359 O+ve ~30% and A+ve ~26%) in Bangladesh.³⁸ So, we assume that the variation in the
360 geographical prevalence of different blood groups might be the reason behind the findings of
361 certain ABO blood groups being more common in certain countries without having any real
362 contribution to COVID-19 susceptibility.

363 An important part of our study was to assess and scrutinize the sample for post-COVID
364 complications- both physical and mental (Table-3 and Table-S2, supplementary file). Our study
365 found that people with comorbidities have reported post-COVID complications such as mobility
366 problems, pain and discomfort, anxiety and depression and indication of memory loss with a
367 greater significance (Table-4). We also found that the vulnerability of recovered individuals
368 towards post COVID complications was due to being comorbid and being exposed to drugs for a
369 prolonged period (Table-4). Although retrieved from a basic questionnaire, the results obtained
370 from this study are statistically significant. Our findings are consistent with data obtained from
371 similar studies in other countries.^{39, 40}

372 Since this study was an onset in regards to epidemiological analysis of COVID-19 patients in
373 Bangladesh, it was prone to some limitations. Firstly, the study sample only included inpatients

374 from 6 selected hospitals providing aid to COVID-19 cases in Bangladesh which narrows down
375 the sample size and diversification in results. Secondly, since the data were collected over the
376 telephone there may be possibilities of information bias, interviewer bias as well as recall bias.
377 Finally, commenting on an individual's health status and complications post COVID-19
378 depending on a four-week recovery period is prompt. Nevertheless, this study aimed to observe
379 the early post- COVID-19 health complications.

380 To date this is the most comprehensive study conducted in Bangladesh that assessed COVID-19
381 patients for both pre-recovery and post-recovery complications. Our data have reconfirmed some
382 significant global observations in regards to the epidemiological and clinical aspects of the
383 disease, but above all, the study has helped in addressing concerns that raised eyebrows
384 including the role of ABO blood group and BCG vaccination in COVID-19 susceptibility and
385 progression. We anticipate that the outcomes of this study will work as a baseline for future
386 studies in the same context.

387

388

389

390

391

392

393

394

395 **Conclusion:**

396

397 To sum up, this study identified the early health complications post recovery in COVID-19
398 patients which yet has aspects that require further assessment and examining for more in-depth
399 insights. This study found that individuals with comorbidities had a hard time coping with the
400 clinical implications imposed while they were with COVID-19. The fact that there is a
401 significant advancement of the number of asymptomatic COVID-19 cases calls for further
402 investigations. The results obtained from this study could contribute to devising effective
403 strategies for the provision of comprehensive health care to COVID-19 patients with
404 comorbidity.

405

406

407

408

409

410

411

412

413

414


415

Table1 Demographics and baseline characteristics of patients diagnosed with COVID-19

| | All patients (N=1021) | Asymptomatic (N=111) | Symptomatic (N=910) | P value* |
|------------------------|--------------------------|-------------------------|------------------------|----------|
| | N (%) | N (%) | N (%) | |
| Age (years) | | | | |
| 0-9 | 18 (1.8) | 8 (7.2) | 10 (1.1) | 0.000 |
| 10-19 | 50 (4.9) | 8 (7.2) | 42 (4.6) | |
| 20-29 | 248 (24.4) | 32 (28.8) | 216 (23.8) | |
| 30-39 | 309 (30.4) | 32 (28.8) | 277 (30.5) | |
| 40-49 | 171 (16.8) | 11 (9.9) | 160 (17.6) | |
| 50-59 | 126 (12.4) | 15 (13.5) | 111 (12.2) | |
| 60 and above | 96 (9.4) | 5 (4.5) | 91 (10) | |
| Gender | | | | |
| Male | 764 (75) | 72 (64.9) | 692 (76.1) | 0.010 |
| Female | 256 (25) | 39 (35.1) | 217 (23.9) | |
| BMI | | | | |
| <18.5 | 20 (2.1) | 4 (4) | 16 (1.9) | 0.475 |
| 18.5 – 22.9 | 258 (27.4) | 29 (29.3) | 229 (27.2) | |
| 23.0 – 26.9 | 434 (46.1) | 43 (43.4) | 391 (46.4) | |
| 27.0 + | 230 (24.4) | 23 (23.2) | 207 (24.6) | |
| Blood group | | | | |
| A+ | 207 (20.9) | 27 (25) | 180 (20.4) | 0.009 |
| A- | 12 (1.2) | 1 (0.9) | 11 (1.2) | |
| AB+ | 92 (9.3) | 4 (3.7) | 88 (10) | |
| AB- | 10 (1) | 4 (3.7) | 6 (0.7) | |
| B+ | 360 (36.3) | 34 (31.5) | 326 (36.9) | |
| B- | 15 (1.5) | 2 (1.9) | 13 (1.5) | |
| O+ | 287 (29) | 33 (30.6) | 254 (28.7) | |
| O- | 9 (0.9) | 3 (2.8) | 6 (0.7) | |
| Vaccinated | 903 (90.4) | 96 (88.9) | 807 (90.6) | 0.575 |
| Having BCG mark | 835 (84.7) | 93 (89.4) | 742 (84.1) | 0.156 |
| Comorbidities | | | | |
| Diabetes | 197 (19.3) | 14 (12.6) | 183 (20.1) | 0.058 |
| Cancer | 10 (1) | 2 (1.8) | 8 (0.9) | 0.298 |
| Cardiovascular disease | 78 (7.7) | 7 (6.3) | 71 (7.8) | 0.573 |
| Respiratory disease | 86 (8.4) | 5 (4.5) | 81 (9) | 0.146 |
| Liver disease | 20 (2) | 0 (0) | 20 (2.2) | 0.154 |
| Kidney disease | 27 (2.7) | 3 (2.7) | 24 (2.6) | 1.000 |
| Other chronic disease | 80 (7.8) | 11 (10) | 69 (7.6) | 0.391 |

We used Fisher's exact test for categorical variables in analyzing P values. P<0.05 was considered statistically significant.

416



417

418

419 **Figure 1-** Frequency of symptomatic and asymptomatic COVID-19 patients at various time points.

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

Table 2 Signs and symptoms of COVID patients

| All patients (N=1021) | N (%) |
|--|------------|
| Sign | |
| Body temperature | |
| <99 ⁰ F | 89 (9.6) |
| 99 ⁰ F – 101 ⁰ F | 368 (39.5) |
| >101 ⁰ F | 474 (51) |
| Oxygen saturation rate | |
| <90% | 80 (19.3) |
| 90%-92.9% | 33 (8) |
| 93%-95.9% | 130 (31.3) |
| >96% | 172 (41.5) |
| Blood pressure | |
| <120; <80 mmHg | 89 (9.5) |
| 120-140; 80-89 mmHg | 796 (85.2) |
| 141-159; 90-99 mmHg | 5 (0.5) |
| >159; >99 mmHg | 44 (4.7) |
| Symptom | |
| Fever | 738 (72.4) |
| Chills | 127 (12.5) |
| Body ache | 407 (40) |
| Cough | 570 (55.9) |
| Sore throat | 242 (23.7) |
| Breathing difficulty | 264 (25.9) |
| Loss of taste | 415 (40.7) |
| Loss of smell | 376 (36.9) |
| Chest pain | 178 (17.5) |
| Running nose | 190 (18.6) |
| Diarrhea | 202 (19.8) |
| Tiredness | 127 (12.5) |
| Vomiting | 116 (11.4) |
| Blurred vision | 40(4) |

435


436

437

438

439

440



441
 442
 443 **Figure 2. Biochemical parameters and medication history of COVID-19 patients.** A)
 444 Various biochemical measurements during onset of COVID-19. Normal reference values are: D-
 445 dimer < 0.5 $\mu\text{g/mL}$, Ferritin -Male 18-370 ng/mL , Female 9- 120 ng/mL ; Serum Creatinine-
 446 Male 0.4-1.4 mg/dL , Female - 0.3 mg -1.1 mg/dL ; CRF: < 5 mg/L ; Troponin: < 0.30 ng/mL ; Uric
 447 acid: Male- 3.4 – 7 mg/dL , Female 2.4 – 6 mg/dL ; ESR: Male < 22 mm/hr , Female < 29 mm/hr ;
 448 SGPT: Male: 15- 65 U/L , Female 15 -60 U/L ; CBC : WBC: 4-11 $\times 10^9/\text{L}$, Neutrophil: 40-75%;
 449 lymphocyte 20-45%, ESR: male 0-10 mm , Female 0-15 mm . B) Medication history of the
 450 patients during the tenure of COVID-19 persistence for cases.

451
 452
 453
 454
 455
 456
 457
 458
 459

460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476

Table 3 post-COVID complications of patients by comorbidity status

| | All patients, (N=1,021) | With comorbidity, (N=358) | Without comorbidity, (N=662) | P value |
|--------------------------------------|----------------------------|---------------------------------|------------------------------------|---------|
| Mobility problem | 179 (17.7) | 93 (26) | 86 (13) | 0.000 |
| Problems performing usual activities | 104 (10.7) | 50 (14) | 54 (8.2) | 0.003 |
| Pain and discomfort | 319 (31.8) | 143 (40) | 176 (26.6) | 0.000 |
| Anxiety and depression | 230 (23.1) | 102 (28.5) | 128 (19.3) | 0.000 |
| Sleep disturbances | 312 (32) | 148 (41.3) | 164 (24.8) | 0.000 |
| Panic attack | 121 (12.4) | 43 (12) | 78 (11.8) | 0.712 |
| Lack of concentration | 243 (24.4) | 102 (28.5) | 141 (21.3) | 0.005 |
| Memory loss | 195 (19.5) | 88 (24.6) | 107 (16.2) | 0.001 |

477

478

Table 4 Adjusted odds ratios for predictors of post-COVID complications

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|--------------------------|--------------------|-------------------------|----------------------|--------------------|--------------------|--------------------|-------------------|
| | Memory loss | Concentration inability | Anxiety & depression | Mobility problem | Activity problem | Sleep disturbance | Pain & discomfort |
| Diabetes | — | — | — | — | — | — | — |
| Cancer | — | — | 0.10* (0.138) | — | — | — | — |
| Cardiovascular disease | — | — | — | — | — | — | — |
| Respiratory disease | 1.70** (0.477) | 1.62* (0.433) | — | — | — | 2.41*** (0.652) | 1.70** (0.445) |
| Kidney disease | — | — | — | — | — | — | — |
| Liver disease | — | — | 9.76*** (6.643) | 6.06*** (3.499) | 5.07*** (2.957) | 2.88* (1.701) | — |
| Other chronic disease | — | — | 1.95** (0.546) | — | — | — | — |
| Prolonged medication use | 1.85*** (0.436) | 1.84*** (0.403) | 1.65** (0.375) | — | — | 2.16*** (0.470) | — |
| No. of observations | 902 | 898 | 894 | 905 | 863 | 872 | 901 |

All models are controlled for age, gender, BMI, vaccination. *** P<0.01, ** P<0.05, * P<0.10, Parentheses include standard errors. Coefficients are reported if they are statistically significant

479

480

481

482

483

484

485

486

487

488

489 **References:**

- 490 1. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, *et al.*
491 SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven
492 protease inhibitor. *Cell*. 2020.
- 493 2. Becerra-Flores M, Cardozo T. SARS-CoV-2 viral spike G614 mutation exhibits
494 higher case fatality rate. *International Journal of Clinical Practice*. 2020.
- 495 3. Forster P, Forster L, Renfrew C, Forster M. Phylogenetic network analysis of SARS-
496 CoV-2 genomes. *Proceedings of the National Academy of Sciences*. 2020; 117(17): 9241-3.
- 497 4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, *et al.* Clinical features of patients infected
498 with 2019 novel coronavirus in Wuhan, China. *The lancet*. 2020; 395(10223): 497-506.
- 499 5. DESA. World population prospects 2019: Highlights. *United Nations Department for*
500 *Economic and Social Affairs*. 2019.
- 501 6. Mondal RN, Sarker MAR, Das A, Ahsan MAK, Jahan SMS, Sultana A, *et al.* Socio-
502 demographic, clinical, hospital admission and oxygen requirement characteristics of COVID-19
503 patients of Bangladesh. *medRxiv*. 2020.
- 504 7. Huq AF, Rahman MF, Islam MA, Iqbal SA, Rahman A, Abdullah SAHM, *et al.* Real-life
505 Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational
506 and Cohort Study. *Euroasian journal of hepato-gastroenterology*. 2020; 10(1): 31.
- 507 8. Yasmin R, Parveen R, Al Azad N, Deb SR, Paul N, Haque MM, *et al.* Corona Virus
508 Infection among Healthcare Workers in a COVID Dedicated Tertiary Care Hospital in Dhaka,
509 Bangladesh. *Journal of Bangladesh College of Physicians and Surgeons*. 2020: 43-9.
- 510 9. yeon Lee J, Hong SW, Hyun M, Park JS, Lee JH, Suh YS, *et al.* Epidemiological and
511 clinical characteristics of coronavirus disease 2019 in Daegu, South Korea. *International Journal*
512 *of Infectious Diseases*. 2020.
- 513 10. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, *et al.*
514 Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with
515 COVID-19 in the New York City area. *Jama*. 2020.
- 516 11. Alkundi A, Mahmoud I, Musa A, Naveed S, Alshawaf M. Clinical characteristics and
517 outcomes of COVID-19 hospitalized patients with diabetes in UK: A retrospective single centre
518 study. *Diabetes Research and Clinical Practice*. 2020.

- 519 12. Marco M, Valentina I, Laura G, Roberto G, Luigi U. Management of diabetic persons
520 with foot ulceration during COVID-19 health care emergency: effectiveness of a new triage
521 pathway. *Diabetes Research and Clinical Practice*. 2020.
- 522 13. Plecher H. Median age of the population in Bangladesh 2015. Statista; 2020`URL].
523 [updated Last Update Date]; cited Accessed Year Access Date]]; Edition:[Description].
- 524 14. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, *et al*. Clinical features and treatment of
525 COVID-19 patients in northeast Chongqing. *Journal of medical virology*. 2020.
- 526 15. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, *et al*.
527 Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory
528 syndrome coronavirus disease from Saudi Arabia: a descriptive study. *The Lancet infectious*
529 *diseases*. 2013; 13(9): 752-61.
- 530 16. Zhao D, Wang M, Wang M, Zhao Y, Zheng Z, Li X, *et al*. Asymptomatic infection by
531 SARS-CoV-2 in healthcare workers: A study in a large teaching hospital in Wuhan, China.
532 *International Journal of Infectious Diseases*. 2020.
- 533 17. Terpos E, Ntanasis Stathopoulos I, Elalamy I, Kastiritis E, Sergentanis TN, Politou M, *et*
534 *al*. Hematological findings and complications of COVID-19. *American journal of hematology*.
535 2020.
- 536 18. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, *et al*. Epidemiological and clinical
537 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive
538 study. *The Lancet*. 2020; 395(10223): 507-13.
- 539 19. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, *et al*. Clinical characteristics of 138
540 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *Jama*.
541 2020; 323(11): 1061-9.
- 542 20. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, *et al*. COVID-19
543 and cardiovascular disease. *Circulation*. 2020; 141(20): 1648-55.
- 544 21. Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D. Elevated
545 troponin in patients with Coronavirus Disease 2019 (COVID-19): possible mechanisms. *Journal*
546 *of Cardiac Failure*. 2020.
- 547 22. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, *et al*. Association of cardiac injury with
548 mortality in hospitalized patients with COVID-19 in Wuhan, China. *JAMA cardiology*. 2020.

- 549 23. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, *et al.* Cardiovascular implications of fatal
550 outcomes of patients with coronavirus disease 2019 (COVID-19). *JAMA cardiology*. 2020.
- 551 24. Kumar-M P, Mishra S, Jha DK, Shukla J, Choudhury A, Mohindra R, *et al.* Coronavirus
552 disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis.
553 *Hepatology international*. 2020: 1-12.
- 554 25. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang Y-Q, *et al.* Lymphopenia predicts
555 disease severity of COVID-19: a descriptive and predictive study. *Signal transduction and*
556 *targeted therapy*. 2020; 5(1): 1-3.
- 557 26. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, *et al.* Clinical course and outcomes of
558 critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,
559 retrospective, observational study. *The Lancet Respiratory Medicine*. 2020.
- 560 27. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, *et al.* Characteristics
561 and outcomes of 21 critically ill patients with COVID-19 in Washington State. *Jama*. 2020;
562 323(16): 1612-4.
- 563 28. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, *et al.* Covid-19
564 in critically ill patients in the Seattle region—case series. *New England Journal of Medicine*.
565 2020; 382(21): 2012-22.
- 566 29. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, *et al.* Clinical characteristics of 24
567 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China.
568 *Science China Life Sciences*. 2020; 63(5): 706-11.
- 569 30. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, *et al.* A familial cluster of
570 pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission:
571 a study of a family cluster. *The Lancet*. 2020; 395(10223): 514-23.
- 572 31. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, *et al.* Clinical characteristics of
573 coronavirus disease 2019 in China. *New England journal of medicine*. 2020; 382(18): 1708-20.
- 574 32. Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, *et al.* Importation
575 and human-to-human transmission of a novel coronavirus in Vietnam. *New England Journal of*
576 *Medicine*. 2020; 382(9): 872-4.
- 577 33. WHO. Bacille Calmette-Guérin (BCG) vaccination and COVID-19: scientific brief, 12
578 April 2020: World Health Organization2020.

- 579 34. O'Neill LA, Netea MG. BCG-induced trained immunity: can it offer protection against
580 COVID-19? *Nature Reviews Immunology*. 2020; 20(6): 335-7.
- 581 35. Wu Y, Feng Z, Li P, Yu Q. Relationship between ABO blood group distribution and
582 clinical characteristics in patients with COVID-19. *Clinica Chimica Acta*. 2020; 509: 220-3.
- 583 36. Göker H, Karakulak EA, Demiroğlu H, Ceylan ÇMA, Büyükaşık Y, Inkaya AÇ, *et al.*
584 The effects of blood group types on the risk of COVID-19 infection and its clinical outcome.
585 *Turkish journal of medical sciences*. 2020; 50(4): 679-83.
- 586 37. Zhao J, Yang Y, Huang H-P, Li D, Gu D-F, Lu X-F, *et al.* Relationship between the ABO
587 Blood Group and the COVID-19 Susceptibility. *medRxiv*. 2020.
- 588 38. Dipta TF, Iqbal MR, Hossain AZ, Rahman MT, Chowdhury S. Distribution of
589 phenotypic and genotypic ABO and Rhesus blood groups among Bangladeshi population.
590 *Ibrahim Medical College Journal*. 2011; 5(2): 59-62.
- 591 39. Jiang DH, McCoy RG. Planning for the Post-COVID Syndrome: How Payers Can
592 Mitigate Long-Term Complications of the Pandemic. *Journal of general internal medicine*.
593 2020: 1-4.
- 594 40. Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19.
595 *Jama*. 2020.

596

597

598

599